My scientific and leadership experience stems from over 25 years of intense, fast-paced direction of research and development teams for both pharmaceutical and contract research organizations. I bring creativity and scientific discipline to the invention of new medicines, and offer a proven track record of success:• Invention of the very first oral, non-retinoid to progress to Phase IIB/III clinical trials for AMD (Emixustat)• Team leader/principal inventor 3 clinical candidates•Head of all non-clinical R&D for Emixustat program (Medicinal and Process Chemistry, Biology, DP formulation and manufacture, analytical, intellectual property, ADME-PK and toxicology). API Development team leader for 16 programs (IND, ANDA and NDA filings)• Author API section for successful NDA filing of Belinostat (Beleodaq)• 35 Issued US patents• 34 Publications and presentations • 6 Invited speaking engagements; Session chair, Neuron to Synapse 2010From R&D to operations, I provide a wide range of scientific knowledge, cross-functional leadership, and management expertise to every aspect of drug discovery and development. My work includes the achievement of ambitious corporate and scientific goals with teams numbering from a just a few scientists, to as many as 60 staff distributed among global research sites. My specialty is the integration of all aspects of drug discovery, from early-stage research in medicinal chemistry, through patent protection, pre-clinical development, API process development and CMC filing from IND through NDA.Specialties: Neurological disease / neurodegeneration ~ Ophthalmic disease ~ Cancer ~ Inflammation {Retinoid Isomerization, RPE65, Kinases (P38, MAPKAP2, MK-2), NMDA, Dopamine D2, Growth Factors (FGF, VEGF), HDAC, Serotonin, Integrin VLA-4/alpha4beta1, PTP-1B, Endothelin A, GABA, E-Selectin, beta-Secretase}